Renal Cell Carcinoma
Conditions
Interventions
Experimental group:Stereotactic Body Radiation Therapy
Sponsors
Cancer Hospital Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. For patients with newly diagnosed M1 or moderately advanced renal cancer with moderate progression on systemic therapy, there is no restriction on the location and number of metastases, but all metastases are required to be safely given a curative radiotherapy dose after radiotherapy evaluation (a/ß value is 3, EQD2>=70Gy) 2. Age>=18 years 3. ECOG 0-3 points 4. Renal malignant tumors confirmed by pathological or imaging examinations, but the subtype is not limited 5. Have evaluable lesions 6. Patients with spinal cord compression or brain metastatic edema that obviously require surgical decompression will be evaluated by the radiotherapy department after decompression, and if the above doses can be safely administered, they can also be enrolled 7. Tolerable to radiotherapy and standard systemic therapy (targeted or target-immune combination therapy) 8. Life expectancy> 6 months 9. Informed consent can be signed 10. There are follow-up conditions
Exclusion criteria
Exclusion criteria: 1. Patients with other comorbidities who are unable to use or tolerate target-immune drugs: allergy to target-free drugs, active bleeding, ulcers, intestinal perforation, intestinal obstruction, uncontrollable hypertension, grade III.-IV cardiac insufficiency (NYHA criteria), severe liver and kidney insufficiency (grade IV), etc 2. The patient has other comorbidities and cannot tolerate radiotherapy 3. Complete response to first-line drug therapy (i.e., there is no treatable target for SABR) 4. Previous history of radiotherapy at the same site 5. Pregnant or lactating women 6. Have other serious medical comorbidities that are unable to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Acute Toxicity;Pain;Life Quality Score;2 Years Overall Survival;2 Years Progression-Free Surial;2 Years Overall Survival; | — |
Countries
China
Contacts
Public ContactXiongjun Ye
Cancer Hospital Chinese Academy of Medical Sciences
Outcome results
None listed